Assessment of Bioequivalence

Assessment of the bioequivalence of generic versions of certain reference drugs is complicated by the presence of endogenous levels of said compounds which cannot be distinguished from externally derived compound levels following drug administration. If unaccounted for, the presence of endogenous compound biases towards equivalence in bioequivalence studies of these drugs. Bioequivalence assessments may be complicated further as disposition of the exogenous analogue can be subject to various endogenous processes resulting in nonlinear pharmacokinetics. To overcome these inherent biases a number of different strategies have been employed. 

  • Solubility based on highest dose strength of an IR product
  • Establishment of bioequivalence criteria
  • Drugs possessing narrow therapeutic index
  • Waivers of In Vivo Study Requirements
  • Biopharmaceutics Classification System (BCS)
  • Topical dosage forms
  • Respiratory dosage forms
  • Transdermal dosage forms
  • Evaluation of highly variable drugs and drug products

Related Conference of Assessment of Bioequivalence

June 06-07, 2018

International Conference & B2B on Pharma Research and Development

Philadelphia, Pennsylvania, USA
June 08-09, 2018

8th International Conference and Exhibition on GMP, GCP & Quality Control

Philadelphia, Pennsylvania, USA
June 08-09, 2018

7th International conference on Pharmaceutical Auditing

Philadelphia, Pennsylvania, USA
June 27-28, 2018

4th International Conference on Drug Discovery, Designing and Development

Vancouver, British Columbia, Canada
August 20-21, 2018

12th Asian Biologics and Biosimilars Congress

Tokyo, Japan
October 18-19, 2018

18th World Pharma Congress

Warsaw, Poland
November 15-16, 2018

14th International Conference on Generic Drugs and Biosimilars

Frankfurt, Germany
September 18-19, 2018

6 th European Biopharma Congress

Amsterdam, Netherlands

Assessment of Bioequivalence Conference Speakers

Recommended Sessions

Related Journals

Are you interested in